Correlation Between Biodexa Pharmaceticals and Quoin Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Biodexa Pharmaceticals and Quoin Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biodexa Pharmaceticals and Quoin Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Biodexa Pharmaceticals and Quoin Pharmaceuticals Ltd, you can compare the effects of market volatilities on Biodexa Pharmaceticals and Quoin Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biodexa Pharmaceticals with a short position of Quoin Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biodexa Pharmaceticals and Quoin Pharmaceuticals.

Diversification Opportunities for Biodexa Pharmaceticals and Quoin Pharmaceuticals

0.1
  Correlation Coefficient

Average diversification

The 3 months correlation between Biodexa and Quoin is 0.1. Overlapping area represents the amount of risk that can be diversified away by holding Biodexa Pharmaceticals and Quoin Pharmaceuticals Ltd in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Quoin Pharmaceuticals and Biodexa Pharmaceticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biodexa Pharmaceticals are associated (or correlated) with Quoin Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Quoin Pharmaceuticals has no effect on the direction of Biodexa Pharmaceticals i.e., Biodexa Pharmaceticals and Quoin Pharmaceuticals go up and down completely randomly.

Pair Corralation between Biodexa Pharmaceticals and Quoin Pharmaceuticals

Given the investment horizon of 90 days Biodexa Pharmaceticals is expected to under-perform the Quoin Pharmaceuticals. In addition to that, Biodexa Pharmaceticals is 1.74 times more volatile than Quoin Pharmaceuticals Ltd. It trades about -0.06 of its total potential returns per unit of risk. Quoin Pharmaceuticals Ltd is currently generating about -0.06 per unit of volatility. If you would invest  1,824  in Quoin Pharmaceuticals Ltd on August 31, 2024 and sell it today you would lose (1,764) from holding Quoin Pharmaceuticals Ltd or give up 96.71% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy99.79%
ValuesDaily Returns

Biodexa Pharmaceticals  vs.  Quoin Pharmaceuticals Ltd

 Performance 
       Timeline  
Biodexa Pharmaceticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Biodexa Pharmaceticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
Quoin Pharmaceuticals 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Quoin Pharmaceuticals Ltd are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Quoin Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Biodexa Pharmaceticals and Quoin Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Biodexa Pharmaceticals and Quoin Pharmaceuticals

The main advantage of trading using opposite Biodexa Pharmaceticals and Quoin Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biodexa Pharmaceticals position performs unexpectedly, Quoin Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Quoin Pharmaceuticals will offset losses from the drop in Quoin Pharmaceuticals' long position.
The idea behind Biodexa Pharmaceticals and Quoin Pharmaceuticals Ltd pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Stocks Directory
Find actively traded stocks across global markets
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance